China Pharma Holdings, Inc.
- Jurisdiction
China - ISIN
US16941T2033 (CPHI )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. Read full profile
Stock price
Fundamentals
- Net revenue
€975.44B - Gross margin
-12.0% - EBIT
-€651.23B - EBIT margin
-66.8% - Net income
-€674.37B - Net margin
-69.1%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 31, 2020